RxDoctor Payments Data

Maureen Considine, OD

Optometrist · South Orange, NJNPI 1083699516

Payments from drug & device makers

$2,210in general payments, 2019–2025

Across 94 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$837
  • AbbVie$507
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$253
  • Eyevance Pharmaceuticals LLC$180
  • Sight Sciences, Inc.$163
  • Oyster Point Pharma, Inc.$76
  • plus $193 from 7 others

What the payments were for

  • Food & beverage$2,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,210 in reported general payments places this provider in the 80th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$112,585
Medicare patients
442
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost48$29,966
RestasisCyclosporine26$29,313
CombiganBrimonidine Tartrate/Timolol21$11,704
Alphagan PBrimonidine Tartrate30$6,282
Brimonidine Tartrate46$5,955
Tobramycin-DexamethasoneTobramycin/Dexamethasone125$4,939
SimbrinzaBrinzolamide/Brimonidine Tart20$4,713
Timolol Maleate161$3,352
Cyclosporine13$3,191
Latanoprost370$3,105
Travoprost19$2,143
Prednisolone Acetate37$1,704
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat115$1,288
Ketorolac Tromethamine45$1,091
Dorzolamide Hcl24$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$507$77,265125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 optometrist providers in New Jersey.

Other optometrist in South Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →